COCP Cocrystal Pharma Inc.

0.51
-0.01  -3%
Previous Close 0.53
Open 0.56
Price To Book 0.26
Market Cap 18,070,645
Shares 35,150,058
Volume 125,626
Short Ratio
Av. Daily Volume 97,456
Stock charts supplied by TradingView

NewsSee all news

  1. Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event

    – Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), ("Cocrystal" or the "Company"), a clinical stage

  2. Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) –  – Preclinical influenza A/B

  3. Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

    - New data presented at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting - - Patients that achieved SVR had significantly higher frequencies of terminally differentiated effector

  4. COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

    BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today

  5. Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting

    New data to be presented from U.S. Phase 2a clinical trial of CC-31244 for ultrashort treatment of hepatitis C virus (HCV)Eight of 12 patients achieved primary endpoint of sustained virologic response (SVR) 12, which is

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a updated data presented AASLD November 10, 2019.
CC-31244
Hepatitis C
Phase 1 trial to be initiated 4Q 2020.
CC-42344
Influenza
Phase 2a enrolment to be completed 1Q 2020 (Hong Kong trial).
CC-31244
Hepatitis C

Latest News

  1. Cocrystal Pharma to Present at the 12th Annual LD Micro Main Event

    – Presentation on Tuesday, December 10th at 4:40 pm PST – BOTHELL, WA, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), ("Cocrystal" or the "Company"), a clinical stage

  2. Cocrystal Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Following new positive data from Phase 2a study, Company outlines next steps in clinical development plan for lead program CC-31244 for ultrashort treatment of hepatitis C (HepC) –  – Preclinical influenza A/B

  3. Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

    - New data presented at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting - - Patients that achieved SVR had significantly higher frequencies of terminally differentiated effector

  4. COCRYSTAL PHARMA, INC. ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

    BOTHELL, WA, Oct. 30, 2019 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ:COCP) ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today

  5. Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting

    New data to be presented from U.S. Phase 2a clinical trial of CC-31244 for ultrashort treatment of hepatitis C virus (HCV)Eight of 12 patients achieved primary endpoint of sustained virologic response (SVR) 12, which is

  6. Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses

    - Novel class of HCV antivirals targeting the NS3 helicase that can be studied for the treatment of chronic HCV infection developed utilizing Company's unique structure-based drug design platform technology - BOTHELL,

  7. Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses

    BOTHELL, WA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today

  8. Cocrystal Pharma to Present at the 2019 Cantor Global Healthcare Conference

    - Presentation on Friday, October 4th at 1:45 PM ET - BOTHELL, WA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP), ("Cocrystal" or the "Company"), a clinical stage biotechnology company

  9. Cocrystal Pharma Presents Positive Preclinical Data for CC-42344 at the Options X for the Control of Influenza Conference

    - CC-42344 showed broad spectrum activity, excellent anti-influenza activity (EC50 <1 nM), and a strong synergistic effect with approved influenza antivirals - - Preclinical study demonstrated favorable